MTVA
What one share of Metavia holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity.
Metavia’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.72 |
|---|---|
| Cash and investments | $1.92 |
| Book value | $1.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$617.70 | — | −$456.21 | — | — |
| 2017 | — | −$774.91 | — | −$623.84 | — | $0.56 |
| 2018 | — | −$876.66 | $0.17 | −$815.97 | — | −$617.14 |
| 2019 | — | −$979.08 | $9.83 | −$333.20 | — | — |
| 2020 | — | −$439.20 | $0.06 | −$159.36 | — | $87.88 |
| 2021 | — | −$158.50 | $0.03 | −$156.98 | — | $131.40 |
| 2022 | — | −$43.42 | — | −$36.41 | — | — |
| 2023 | — | −$2.46 | $0.01 | −$2.14 | — | $3.40 |
| 2024 | — | −$39.13 | $0.01 | −$35.05 | — | $10.10 |
| 2025 | — | −$7.35 | $0.00 | −$8.89 | — | $2.31 |